Table 2. Comparison between survival outcomes of the main phase III trials and Markar’s analysis.

Trial	Trial design	mOS (months)	Years OS (%)	PFS or DFS	Loco-regional failure (%)	Local relapse (%)	Distance recurrence (%)
RTOG 85-01, N=134 (2)	CRT vs. RT	14 vs. 9	5-year OS: 26 vs. 0	–	26 vs. 37	47 vs. 65	–
INT 0123, N=218 (3)	CRT (50.4 Gy) vs. CRT (64.8 Gy)	13 vs. 18	2-year OS: 31 vs. 40	–	56 vs. 52	–	–
Stahl 2005, N=172 (19)	CT-CRT-surg vs. CT-CRT	–	2-year OS: 39.9 vs. 35.4 (NS)	2-year local PFS rate: 64.3 vs. 40.7 (P=0.003)	–	–	–
FFCD 9102, N=444 (4)	CRT rand to Surg vs. Def CRT	17.7 vs. 19.3	2-year OS: 33.6 vs. 39.8 (P=0.03)	2-year local control rate: 66.4 vs. 57	–	–	–
Stahl 2009, N=354 (20)	CT-surg vs. CT-CRT-surg	–	3-year OS 27.7 vs. 47.4	–	–	–	–
Van Hagen, N=368 (5)	CRT-surg vs. surg	49.4 vs. 24 (P=0.003)	–	mDFS: not reached vs. 24.2 (P<0.001)	–	85 vs. 94 (NS)	–
FFCD 9901, N=195 (14)	CRT-surg vs. surg	31.8 vs. 41.2 (NS)	3-year OS: 47.5 vs. 53 (NS); 5-year OS: 41.1 vs. 33.8 (NS)	mDFS: 27.8 vs. 26.7 (NS); 5-year DFS: 35.6 vs. 27.7 (NS)	–	15.3 vs. 28.9 (P=0.02)	22.5 vs. 28.9 (NS)
Markar, N=2,944 (18)	(I) S vs. NS; (II) SCC vs. AC; (III) NEO CRT vs. CHT	(I) 43.3 vs. 39.2 (NS); (II) No OS difference; (III) No OS difference	5-year OS: 44 vs. 41 (NS)	(I) 40.9 vs. 39.2 (NS); (II) no DFS difference; (III) no DFS difference	–	20.4 vs. 20.3 (NS)	18.9 vs. 20.7 (NS)

CRT, chemoradiation; CHT, chemotherapy; SCC, squamous cell carcinoma; OS, overall survival; PFS, progression free survival; DFS, disease free survival; NS, not